[EN] CANNABINOID RECEPTOR INVERSE AGONISTS AND NEUTRAL ANTAGONISTS AS THERAPEUTIC AGENTS FOR THE TREATMENT OF BONE DISORDERS<br/>[FR] AGONISTES INVERSES DE RECEPTEURS DE CANNABINOIDES ET ANTAGONISTES NEUTRES AGISSANT EN TANT QU'AGENTS THERAPEUTIQUES DESTINES AU TRAITEMENT DE TROUBLES OSSEUX
申请人:UNIV ABERDEEN
公开号:WO2004078261A1
公开(公告)日:2004-09-16
The present invention pertains to cannabinoid (CB) receptor inverse agonists and neutral antagonists, and especially CB1 and CB2 inverse agonists and neutral antagonists; such as, for example, certain pyrazole compounds; their use in the inhibition of osteoclasts (for example, the inhibition of the survival, formation, and/or activity of osteoclasts), and/or in the inhibition of bone resorption; their use in connection with treatment of bone disorders, such as conditions mediated by osteoclasts (e.g., increased osteoclast activity) and/or characterised by (e.g., increased) bone resorption, such as osteoporosis (e.g., osteoporosis not associated with inflammation; e.g., osteoporosis associated with a genetic predisposition, sex hormone deficiency, or ageing), cancer associated bone disease, and Paget's disease of bone.